Stoke Therapeutics (STOK) Revenue Growth (1y) (2023 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Revenue Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 16.50% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 296.11% |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | -32.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.51% |
| Mar 31, 2026 | -96.07% |
| Dec 31, 2025 | -93.80% |
| Sep 30, 2025 | 117.25% |
| Jun 30, 2025 | 186.01% |
| Mar 31, 2025 | 3,661.12% |
| Dec 31, 2024 | 707.07% |
| Sep 30, 2024 | 47.94% |
| Jun 30, 2024 | 94.72% |
| Mar 31, 2024 | -18.17% |
| Dec 31, 2023 | -14.26% |
| Sep 30, 2023 | 13.87% |
| Jun 30, 2023 | -23.21% |
| Mar 31, 2023 | 71.73% |